PATENT CLAIM ANALYSIS

Application Number: 15952616
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["546", "138000"]

Abstract:
Disclosed herein are compounds of Formula I wherein R 1 , R 2 , X, and Y are defined herein. These compounds are type II topoisomerase inhibitors and can be used in methods for treating infections caused by gram-positive pathogens, gram-negative pathogens, and drug-resistant strains thereof.

Claim (Index 40):
The method of  claim 31 , wherein the pathogen is selected from the group consisting of  Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Stenotrophomonas maltophilia, Bacillus anthracis, Brucella abortus, Burkholderia mallei, Burkholderia pseudomallei, Francisella tularensis , and  Yersinia pestis.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.34211
- Patent Class: 546.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15191067', '13821250', '12246778', '15500870', '10767638']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8480308076650988
- 35 USC 102 Novelty (BERT): 0.5419652694625401
- Combined Prediction Score: 0.8174242538448429
- Mean Citation Score: 375.741072
- Max Citation Score: 416.85693
- Similarity Product: 305.77136771611333

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test